In Trusts We Trust: Controlling When Your Kids Get Your Money
Break's Over, Santa: Ticketmaster Kicks Off Christmas Season in May
Consumer Spending Forecast to Boost U.S. Economy
5 Signs That Your Investment Adviser Is Scamming You
NASDAQ: AMRN
2013 FDA Drug Approval Calendar
StockCall Pre-Market Review on AMRN, ARAY, ATRS, and ANTH (NAS,NAS,NAS,NAS:AMRN,ARAY,ATRS,ANTH)
Amarin shares slip after FDA updates Orange Book
Amarin management to meet with Lazard Capital
Amarin strength attributed to MassHealth drug list addition
MKM Partners Slighly Increases Amarin (AMRN) Vascepa Estimates Post Q1
Amarin continues to make progress with payors, says Leerink
Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
Amarin Corporation CEO Discusses Q1 2013 Results - Earnings Call Transcript
Amarin reports Q1 EPS (41c), consensus (39c)